The Italian multiregional thalassemia registry: Centers characteristics, services, and patients’ population

Rosa Conte, Lucia Ruggieri, Arianna Gambino, Franco Bartoloni, Paola Baiardi, Donato Bonifazi, Fedele Bonifazi, Mariagrazia Felisi, Viviana Giannuzzi, Rosa Padula, Alessia Pepe, Maria Caterina Putti, Giovanni Carlo Del Vecchio, Aurelio Maggio, Aldo Filosa, Angela Iacono, Laura Mangiarini, Adriana Ceci

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: The prognosis of beta-Thalassemia major and other congenital hemoglobinopathies has profoundly changed over the last decades. Moreover, only few countries in Europe provide dedicated services and the description of the measures for patients monitoring and treatment is overall very scarce. The HTA-Thal project is aimed to identify the services available in Italy and to collect epidemiological and clinical data on the thalassemic population (HTA-Thal Registry). Methods: A map of the existing centers was created and two electronic questionnaires were completed with information on the services and patients. Results: On 182 centers identified, 60 completed the two questionnaires. Centers resulted to be extremely heterogeneous in terms of size, age of patients in care, and services availability. The transition of pediatric patients to adult centers was not guaranteed. Thousand eight hundred and seventy-three beta-Thalassemia major patients (of which 259 pediatrics), regularly transfused, were registered. Deferasirox is the most used chelator as monotherapy (616 patients) and its use prevails in younger patients. A higher number of patients (847 patients) use Deferoxamine, either alone (448 patients) or in combination with DFP (399 patients), while 782 patients use Deferiprone alone (383 patients) or in combination (399 patients). 31.6 and 66.6% of centers were not equipped for specialized visits or local MRI, respectively. Centers with 30–80 patients show the high percentage of patients appropriately monitored when compared to smaller or bigger centers. Conclusions: This analysis confirms the importance of patients’ registries for the collection of large datasets and the need for dedicated ‘specialized centers’ equipped to provide the best standard treatment to patients.

Original languageEnglish
Pages (from-to)415-424
Number of pages10
JournalHematology
Volume21
Issue number7
DOIs
Publication statusPublished - Aug 8 2016

Fingerprint

Thalassemia
Registries
Population
beta-Thalassemia
Pediatrics
Isoflurophate
Patient Transfer
Hemoglobinopathies
Deferoxamine
Information Services
Physiologic Monitoring
Chelating Agents
Italy

Keywords

  • Beta-Thalassemia
  • Chelation
  • Hemoglobinopathies centers
  • MRI
  • Registries
  • Transfusion

ASJC Scopus subject areas

  • Hematology

Cite this

The Italian multiregional thalassemia registry : Centers characteristics, services, and patients’ population. / Conte, Rosa; Ruggieri, Lucia; Gambino, Arianna; Bartoloni, Franco; Baiardi, Paola; Bonifazi, Donato; Bonifazi, Fedele; Felisi, Mariagrazia; Giannuzzi, Viviana; Padula, Rosa; Pepe, Alessia; Putti, Maria Caterina; Del Vecchio, Giovanni Carlo; Maggio, Aurelio; Filosa, Aldo; Iacono, Angela; Mangiarini, Laura; Ceci, Adriana.

In: Hematology, Vol. 21, No. 7, 08.08.2016, p. 415-424.

Research output: Contribution to journalArticle

Conte, R, Ruggieri, L, Gambino, A, Bartoloni, F, Baiardi, P, Bonifazi, D, Bonifazi, F, Felisi, M, Giannuzzi, V, Padula, R, Pepe, A, Putti, MC, Del Vecchio, GC, Maggio, A, Filosa, A, Iacono, A, Mangiarini, L & Ceci, A 2016, 'The Italian multiregional thalassemia registry: Centers characteristics, services, and patients’ population', Hematology, vol. 21, no. 7, pp. 415-424. https://doi.org/10.1080/10245332.2015.1101971
Conte, Rosa ; Ruggieri, Lucia ; Gambino, Arianna ; Bartoloni, Franco ; Baiardi, Paola ; Bonifazi, Donato ; Bonifazi, Fedele ; Felisi, Mariagrazia ; Giannuzzi, Viviana ; Padula, Rosa ; Pepe, Alessia ; Putti, Maria Caterina ; Del Vecchio, Giovanni Carlo ; Maggio, Aurelio ; Filosa, Aldo ; Iacono, Angela ; Mangiarini, Laura ; Ceci, Adriana. / The Italian multiregional thalassemia registry : Centers characteristics, services, and patients’ population. In: Hematology. 2016 ; Vol. 21, No. 7. pp. 415-424.
@article{3e9dc196974549d3b9c97aeb48039636,
title = "The Italian multiregional thalassemia registry: Centers characteristics, services, and patients’ population†",
abstract = "Objectives: The prognosis of beta-Thalassemia major and other congenital hemoglobinopathies has profoundly changed over the last decades. Moreover, only few countries in Europe provide dedicated services and the description of the measures for patients monitoring and treatment is overall very scarce. The HTA-Thal project is aimed to identify the services available in Italy and to collect epidemiological and clinical data on the thalassemic population (HTA-Thal Registry). Methods: A map of the existing centers was created and two electronic questionnaires were completed with information on the services and patients. Results: On 182 centers identified, 60 completed the two questionnaires. Centers resulted to be extremely heterogeneous in terms of size, age of patients in care, and services availability. The transition of pediatric patients to adult centers was not guaranteed. Thousand eight hundred and seventy-three beta-Thalassemia major patients (of which 259 pediatrics), regularly transfused, were registered. Deferasirox is the most used chelator as monotherapy (616 patients) and its use prevails in younger patients. A higher number of patients (847 patients) use Deferoxamine, either alone (448 patients) or in combination with DFP (399 patients), while 782 patients use Deferiprone alone (383 patients) or in combination (399 patients). 31.6 and 66.6{\%} of centers were not equipped for specialized visits or local MRI, respectively. Centers with 30–80 patients show the high percentage of patients appropriately monitored when compared to smaller or bigger centers. Conclusions: This analysis confirms the importance of patients’ registries for the collection of large datasets and the need for dedicated ‘specialized centers’ equipped to provide the best standard treatment to patients.",
keywords = "Beta-Thalassemia, Chelation, Hemoglobinopathies centers, MRI, Registries, Transfusion",
author = "Rosa Conte and Lucia Ruggieri and Arianna Gambino and Franco Bartoloni and Paola Baiardi and Donato Bonifazi and Fedele Bonifazi and Mariagrazia Felisi and Viviana Giannuzzi and Rosa Padula and Alessia Pepe and Putti, {Maria Caterina} and {Del Vecchio}, {Giovanni Carlo} and Aurelio Maggio and Aldo Filosa and Angela Iacono and Laura Mangiarini and Adriana Ceci",
year = "2016",
month = "8",
day = "8",
doi = "10.1080/10245332.2015.1101971",
language = "English",
volume = "21",
pages = "415--424",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - The Italian multiregional thalassemia registry

T2 - Centers characteristics, services, and patients’ population†

AU - Conte, Rosa

AU - Ruggieri, Lucia

AU - Gambino, Arianna

AU - Bartoloni, Franco

AU - Baiardi, Paola

AU - Bonifazi, Donato

AU - Bonifazi, Fedele

AU - Felisi, Mariagrazia

AU - Giannuzzi, Viviana

AU - Padula, Rosa

AU - Pepe, Alessia

AU - Putti, Maria Caterina

AU - Del Vecchio, Giovanni Carlo

AU - Maggio, Aurelio

AU - Filosa, Aldo

AU - Iacono, Angela

AU - Mangiarini, Laura

AU - Ceci, Adriana

PY - 2016/8/8

Y1 - 2016/8/8

N2 - Objectives: The prognosis of beta-Thalassemia major and other congenital hemoglobinopathies has profoundly changed over the last decades. Moreover, only few countries in Europe provide dedicated services and the description of the measures for patients monitoring and treatment is overall very scarce. The HTA-Thal project is aimed to identify the services available in Italy and to collect epidemiological and clinical data on the thalassemic population (HTA-Thal Registry). Methods: A map of the existing centers was created and two electronic questionnaires were completed with information on the services and patients. Results: On 182 centers identified, 60 completed the two questionnaires. Centers resulted to be extremely heterogeneous in terms of size, age of patients in care, and services availability. The transition of pediatric patients to adult centers was not guaranteed. Thousand eight hundred and seventy-three beta-Thalassemia major patients (of which 259 pediatrics), regularly transfused, were registered. Deferasirox is the most used chelator as monotherapy (616 patients) and its use prevails in younger patients. A higher number of patients (847 patients) use Deferoxamine, either alone (448 patients) or in combination with DFP (399 patients), while 782 patients use Deferiprone alone (383 patients) or in combination (399 patients). 31.6 and 66.6% of centers were not equipped for specialized visits or local MRI, respectively. Centers with 30–80 patients show the high percentage of patients appropriately monitored when compared to smaller or bigger centers. Conclusions: This analysis confirms the importance of patients’ registries for the collection of large datasets and the need for dedicated ‘specialized centers’ equipped to provide the best standard treatment to patients.

AB - Objectives: The prognosis of beta-Thalassemia major and other congenital hemoglobinopathies has profoundly changed over the last decades. Moreover, only few countries in Europe provide dedicated services and the description of the measures for patients monitoring and treatment is overall very scarce. The HTA-Thal project is aimed to identify the services available in Italy and to collect epidemiological and clinical data on the thalassemic population (HTA-Thal Registry). Methods: A map of the existing centers was created and two electronic questionnaires were completed with information on the services and patients. Results: On 182 centers identified, 60 completed the two questionnaires. Centers resulted to be extremely heterogeneous in terms of size, age of patients in care, and services availability. The transition of pediatric patients to adult centers was not guaranteed. Thousand eight hundred and seventy-three beta-Thalassemia major patients (of which 259 pediatrics), regularly transfused, were registered. Deferasirox is the most used chelator as monotherapy (616 patients) and its use prevails in younger patients. A higher number of patients (847 patients) use Deferoxamine, either alone (448 patients) or in combination with DFP (399 patients), while 782 patients use Deferiprone alone (383 patients) or in combination (399 patients). 31.6 and 66.6% of centers were not equipped for specialized visits or local MRI, respectively. Centers with 30–80 patients show the high percentage of patients appropriately monitored when compared to smaller or bigger centers. Conclusions: This analysis confirms the importance of patients’ registries for the collection of large datasets and the need for dedicated ‘specialized centers’ equipped to provide the best standard treatment to patients.

KW - Beta-Thalassemia

KW - Chelation

KW - Hemoglobinopathies centers

KW - MRI

KW - Registries

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=84978493312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978493312&partnerID=8YFLogxK

U2 - 10.1080/10245332.2015.1101971

DO - 10.1080/10245332.2015.1101971

M3 - Article

AN - SCOPUS:84978493312

VL - 21

SP - 415

EP - 424

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 7

ER -